Filing Flows › AIM ImmunoTech (AIM) › Q1 2026 › vs Q4 2025
AIM ImmunoTech (AIM) Q1 2026 vs Q4 2025 (quarter over quarter)
AIM ImmunoTech's revenue rose $1K (+5%) from $21K in Q4 2025 to $22K in Q1 2026.
AIM ImmunoTech, Q1 2026: revenue $22K (+38% year over year), net loss $3.0M, operating cash flow −$2.7M. The chart draws each line against Q4 2025, the increases inside each band.
Every line
| Line | Q1 2026 | Q4 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $22K | $21K | $1K | +5% |
| Net loss | $3.0M | $4.2M | −$1.2M | -28% |
| Costs & expenses | $3.0M | $4.2M | −$1.2M | -27% |
| Operating costs | $2.2M | $3.0M | −$725K | -24% |
| Interest & other, net | $797K | $1.2M | −$426K | -35% |
| Research & development | $482K | $1.1M | −$581K | -55% |
| General & admin | $1.8M | $1.9M | −$108K | -6% |
| Operating cash sources | $3.0M | $4.2M | −$1.2M | -28% |
| Depreciation & amortization | $43K | $43K | $0 | 0% |
| Working capital & other | $261K | $2.1M | −$1.9M | -88% |
| Cash used in operations | $2.7M | $2.0M | $733K | +37% |
| Net loss absorbed | $3.0M | $4.2M | −$1.2M | -28% |
Questions
How much did AIM ImmunoTech's revenue grow quarter over quarter in Q1 2026?
AIM ImmunoTech's revenue rose $1K (+5%) from $21K in Q4 2025 to $22K in Q1 2026.